EUVIMEDEUVIMED entdecken
KommentarMetaanalyseOpen Access · CC BY 4.0

Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'

James A Watson iD, Robert J Commons iD, Joel Tarning iD, Julie A Simpson iD, Alejandro Llanos Cuentas iD, Marcus V G Lacerda iD, Justin A Green, Gavin C K W Koh iD, Cindy S Chu iD, François H Nosten iD, Richard N Price iD, Nicholas P J Day iD und 1 weitere

eLife · 2024

DOI: 10.7554/elife.91283 ↗

Kurz gefasst

Kommentar in der Zeitschrift eLife, 2024. Verfasst von James A Watson und 12 weiteren Autor:innen. Beteiligte Einrichtung: Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh, Viet Nam. Hauptthemen laut MEDLINE: Aminoquinolines, Antimalarials, Malaria, Vivax. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In our recent paper on the clinical pharmacology of tafenoquine (Watson et al., 2022), we used all available individual patient pharmacometric data from the tafenoquine pre-registration clinical efficacy trials to characterise the determinants of anti-relapse efficacy in tropical vivax malaria. We concluded that the currently recommended dose of tafenoquine (300 mg in adults, average dose of 5 mg/kg) is insufficient for cure in all adults, and a 50% increase to 450 mg (7.5 mg/kg) would halve the risk of vivax recurrence by four months. We recommended that clinical trials of higher doses should be carried out to assess their safety and tolerability. Sharma and colleagues at the pharmaceutical company GSK defend the currently recommended adult dose of 300 mg as the optimum balance between radical curative efficacy and haemolytic toxicity (Sharma et al., 2024). We contend that the relative haemolytic risks of the 300 mg and 450 mg doses have not been sufficiently well characterised to justify this opinion. In contrast, we provided evidence that the currently recommended 300 mg dose results in sub-maximal efficacy, and that prospective clinical trials of higher doses are warranted to assess their risks and benefits.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminoquinolinesAntimalarialsMalaria, VivaxAdultHumansHemolysisPrimaquineProspective StudiesMeta-Analysis as Topic

Stichwörter der Autor:innen

Plasmodium vivax malariaepidemiologyglobal healthhaemolysishumaninfectious diseasemicrobiologyradical curetafenoquine

Substanzen

AminoquinolinesAntimalarialsPrimaquinetafenoquine

Autor:innen und Institutionen

  • Oxford University Clinical Research Unit, Hospital for Tropical Diseases, Ho Chi Minh, Viet Nam.
  • Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom.
  • WorldWide Antimalarial Resistance Network, Oxford, United Kingdom.
  • Global Health Division, Menzies School of Health Research, Charles Darwin University, Darwin, Australia.
  • Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.
  • Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Australia.

ORCID-Profile: James A Watson, Robert J Commons, Joel Tarning, Julie A Simpson, Alejandro Llanos Cuentas, Marcus V G Lacerda, Gavin C K W Koh, Cindy S Chu, François H Nosten, Richard N Price, Nicholas P J Day, Nicholas J White

Förderung

  • Wellcome Trust

Zitieren

APA

Watson, J. A., Commons, R. J., Tarning, J., Simpson, J. A., Llanos Cuentas, A., Lacerda, M. V. G., Green, J. A., Koh, G. C. K. W., Chu, C. S., Nosten, F. H., Price, R. N., Day, N. P. J., & White, N. J. (2024). Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'. eLife. https://doi.org/10.7554/elife.91283

Vancouver

Watson JA, Commons RJ, Tarning J, Simpson JA, Llanos Cuentas A, Lacerda MVG, et al. Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'. eLife. 2024. doi:10.7554/elife.91283

BibTeX
@article{Watson2024,
  author = {Watson, James A and Commons, Robert J and Tarning, Joel and Simpson, Julie A and Llanos Cuentas, Alejandro and Lacerda, Marcus V G and Green, Justin A and Koh, Gavin C K W and Chu, Cindy S and Nosten, François H and Price, Richard N and Day, Nicholas P J and White, Nicholas J},
  title = {Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'},
  journal = {eLife},
  year = {2024},
  doi = {10.7554/elife.91283}
}
Kostenlos starten →